Publication | Closed Access

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

Hematological MalignancyBone Marrow FailureMalignant Blood DisorderImmunologyHematologyLow-risk Myelodysplastic SyndromesAll- TransInterferon AlphaMedicineCell TransplantationMyeloid Neoplasia